Key facts
- Excelsior Sciences’s last known valuation is $96.0M (Dec 2025).
- It has raised $70.0M; the latest was Grant ($25.0M) in Dec 2025.
- Notable investors include Khosla Ventures, Massachusetts Institute of Technology, Sofinnova Partners, Deerfield Management, Illinois Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Excelsior Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Excelsior Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Excelsior Sciences
Operator of an automated chemistry platform intended to accelerate the discovery and manufacture of small molecules. The company offers modular, synthesis-ready and AI-readable chemical building blocks used as tokens in a machine-executable chemical language, enabling researchers and industries working with small molecules to speed up development, generate new functional possibilities, and achieve more efficient and sustainable outcomes.
- Sector
- Business Products and Services (B2B)
- HQ
- New York, NY, United States
- Founded
- 2024
- Employees
- 18
- Website
- excelsiorsci.com/
- Ownership
- Privately Held (backing)
Excelsior Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Excelsior Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Excelsior Sciences in its N-PORT filings yet. We sweep new filings monthly.